ALERT: We have made the Texas Children’s Health Plan website even easier to use! Click here to learn more.
ALERTA: ¡Ahora el sitio web de Texas Children’s Health Plan es aún más sencillo de usar! Haz clic aquí para más información.
Date: December 20, 2022
Attention: All Providers
Effective date: January 1, 2023
Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: On January 1, 2023, the Texas Health and Human Services Commission (HHSC) will designate one medication as the preferred direct-acting antiviral (DAA) drug option for treating Hepatitis C infection. HHSC will designate all other DAA drugs on the Medicaid formulary as non-preferred. Managed care organizations like Texas Children’s Health Plan are required to follow HHSC’s preferred drug list (PDL).
Drug Name | Jan 1, 2023 PDL status |
Mavyret | Preferred |
Epclusa | Non-Preferred |
Vosevi | Non-Preferred |
How this impacts providers: All Medicaid clients are eligible for DAA treatment with the primary preferred agent regardless of the client’s METAVIR fibrosis score, and prior authorization (PA) is not required. Any enrolled Medicaid provider can prescribe the preferred drug, and a drug screening is not required.
Any active members taking Epclusa/Voesvi will need to be switched to Mavyret. Providers must follow these next steps:
Next steps for providers: Providers should notify their members of the medication therapy change and submit new prescriptions to the pharmacy for Mavyret before January 1. If the member meets criteria to obtain a non-preferred product, the provider must submit a PDL prior authorization request as quickly as possible to avoid delay of care. If the member does not meet the exception criteria, the provider must submit an appeal and provide medical necessity rationale before January 1.
If you have any questions, please email TCHP Pharmacy at: TCHPPharmacy@texaschildrens.org.
For access to all provider alerts,log into:
www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers.
For access to the PDL Hepatitis C prior authorization form: Log into the Navitus provider portal, or visit txstarchip.navitus.com, click “Prior Authorization Forms”, and select the “Hep C Agents (PDL)” prior authorization request.